Myriad Genetics News

Myriad Pharmaceuticals Inc. filed Quarterly Report for the period ended 2009-09-30. Myriad Pharmaceuticals, Inc.

The case revolves around seven patents relating to human genes BRCA1 and BRCA2, mutations of which have been tied to breast and ovarian cancer.

In May, the ACLU announced that it was suing to invalidate a patent that covers testing for genetic variants associated with breast cancer.

A federal district judge ruled yesterday that a lawsuit challenging patents on genes related to hereditary breast and ovarian cancer can move forward in court.

A federal judge ruled Monday that a lawsuit can move forward against the Patent and Trademark Office and the research company that was awarded exclusive rights to human genes known to detect early signs of breast and ovarian cancer.

The recommendations were supported by a variety of health professionals but put the biotechnology industry on edge.

Myriad Genetics, Inc. today announced it has obtained from Johns Hopkins University a world-wide, exclusive license to patents covering mutations in the PALB2 gene that increase an individual's risk for developing pancreatic cancer later in life.

Myriad Pharmaceuticals, Inc. today announced the identification of an Investigational New Drug candidate targeting a novel molecular target, the protein kinase IKK epsilon.

Myriad Genetics, Inc. today announced that it will release its fiscal 2010 first quarter financial results at the close of market on Tuesday, November 3, 2009.

Seats are filling fast for The Utah Technology Council's 11th annual Hall of Fame black-tie gala with Eric Schmidt, Chairman of the Board and CEO of Google Inc., as the keynote speaker.

Many women have credited a genetic test with saving their lives. A simple blood sample can determine whether a woman carries a gene that's linked to breast and ovarian cancer.

Myriad Genetics, Inc. announced today that it has elected Louise Phanstiel and Lawrence Best to its Board of Directors, effective September 16, 2009, increasing the size of the Company's board from eight members to 10.

Have researchers been barking up the wrong tree? Alzheimer's disease is a bit like a murder mystery with numerous possible culprits and only a few vague clues.

On this day, we have begun tracking the following companies as they have shown remarkable correction in recent days, you can access these free reports with a number of other reviews by signing up for your complimentary membership at : http://www.rothmanresearch.com/ Companies been researched today are: Myriad Genetics Inc.

Myriad Pharmaceuticals Inc.'s experimental AIDS drug, the first in a new class of medicines for drug-resistant HIV, cut the virus as much as 50-fold in two weeks, a study showed.

Every private portfolio needs to have at least some exposure to each sector and class of security .

Editor's note: An earlier version of this article was written and edited while trading of shares of Facet was halted.

September 1, 2009 - Myriad Group AG , a global leader in mobile technology with software in over 2 billion phones, today announced the appointment of James Bodha as its new Chief Financial Officer , effective September 2nd.

Williams-Sonoma announced better than expected second quarter results, and boosted its forward guidance.

The US Preventive Services Task Force recommends screening mammography every one to two years for women 40 and older.